No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 9
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Jade Biosciences, Inc. (JBIO) stock was $13.54 as of Oct 6, 2026, 12:00 PM EDT, down 3.79% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +58.5% · 3-year avg -66.8%/yr · 5-year avg -52.6%/yr
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.
Biotechnology · Waltham, MA
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.73
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.76
vs Estimate
$-0.64
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1JBIO | $823.83M | $13.54 | -3.79% | +58.45% | -52.65% | N/A | N/A |
| 2PACB | $819.99M | $2.64 | -8.01% | +92.02% | -35.20% | -10.80% | vs JBIO |
| 3ARDX | $815.07M | $3.30 | -2.67% | -35.42% | +20.95% | -0.20% | vs JBIO |
| 4ALMS | $838.75M | $6.80 | -0.65% | +69.72% | N/A | N/A | vs JBIO |
| 5INMD | $804.44M | $13.99 | -0.96% | -6.70% | -27.48% | N/A | vs JBIO |
| 6BBNX | $846.26M | $18.81 | -0.74% | -14.80% | N/A | N/A | vs JBIO |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 8 analysts
Average Price Target
$50.13
+270.3% upside
Low
$40.00
Current
$13.54
High
$77.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.83 | $-0.73 | $-0.57 | 3 |
| Quarter ending Dec 2026 | $-0.86 | $-0.75 | $-0.53 | 3 |
| Quarter ending Mar 2027 | $-0.75 | $-0.75 | $-0.75 | 1 |
| Quarter ending Jun 2027 | $-0.78 | $-0.78 | $-0.78 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-3.30 | $-2.95 | $-2.46 | 4 |
| FY 2027 | $-3.60 | $-2.92 | $-2.06 | 5 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
